Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF launches PrimeStore® MTM pathogenic sample collection and transportation kit

New sample collection kit enables convenient and safe collection, transportation and handling of pathogenic samples including COVID-19 and influenza.

PrimeStore® MTM successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing capacity

What is the difference between standard Viral and Molecular Transport Media?

To support the increase in COVID-19 testing globally, a safe and easy sample collection and transport mechanism is essential. Learn how PrimeStore^® MTM, a novel viral transport media, enables safe molecular testing for multiple pathogens from one sample swab when compared to standard viral transport media.

EKF introduces novel molecular transport media for dual COVID-19 and influenza sampling

Patented PrimeStore^® MTM technology enables safe sample handling and testing for multiple pathogens from one sample swab

EKF opens for live chats at ENDO Online 2020

Patented PrimeStore^® MTM sample collection device deactivates samples for safe sample handling and transport